• Earnings per share (EPS) of -$0.58, aligning with estimates, reflecting ongoing financial challenges.
• Revenue reported at approximately $3.55 million, slightly below expectations, amidst a negative price-to-earnings (P/E) ratio of -4.39.
• Strategic focus on the global development program for JNJ-1900 (NBTXR3) and the launch of Curadigm to ensure long-term sustainability and growth.

Nanobiotix (NASDAQ:NBTX), a biotechnology company specializing in nanoparticle-based treatments for cancer, is navigating through financial challenges while focusing on developing innovative therapies, particularly in oncology. Despite its promising pipeline targeting diseases like head and neck cancer and lung cancer, the company's recent earnings report reflects these financial hurdles.

On April 2, 2025, NBTX reported an earnings per share (EPS) of -$0.58, aligning with the estimated EPS. The company's revenue was approximately $3.55 million, slightly below expectations. This performance is consistent with its negative price-to-earnings (P/E) ratio of -4.39, indicating ongoing financial difficulties.

Nanobiotix is actively working on its global development program for JNJ-1900 (NBTXR3), targeting significant opportunities in the oncology market. The company is implementing a disciplined financial strategy, including focused capital allocation and amending its global licensing agreement for JNJ-1900. This approach aims to ensure long-term sustainability and growth.

The company has launched Curadigm, a next-generation nanotherapeutic platform, to innovate drug design and development. With a cash runway extended into mid-2026 and a reduction in operational cash burn expected, Nanobiotix is positioning itself for future growth. As of December 31, 2024, the company held €49.7 million in cash and cash equivalents.

In 2025, Nanobiotix anticipates clinical data readouts from Phase 1 and 2 studies in various cancer types. A conference call and webcast are scheduled for April 3, 2025, to discuss these updates. Despite financial challenges, the company remains committed to advancing its innovative treatments and achieving long-term success.